# PTGX catalysts: Protagonist Therapeutics, Inc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ptgx/catalysts

> Protagonist Therapeutics, Inc (PTGX) has no upcoming catalysts in this calendar. The latest recorded is the MIMRYLO™ (rusfertide) FDA approval, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Protagonist Therapeutics, Inc |
| Ticker | PTGX (Nasdaq) |
| SEC CIK | 1377121 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ptgx |

## Cash runway

Cash $834.6M as of 2026-09-30; quarterly burn $23.2M; about 107.8 months of runway at that rate (XBRL company facts, accession 0001104659-26-123620).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2023 | [Protagonist Therapeutics, Inc topline data readout](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed, positive | "In March 2023, we announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of the REVIVE trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm)) |
| Jul 2023 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | PTGX |  | completed, positive | "In July 2023, we announced updated positive topline results from the trial, which were presented by JNJ at the World Congress of Dermatology in Singapore." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm)) |
| November 18, 2024 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | PTGX |  | completed, positive | "Calif. - November 18, 2024 - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from its collaboration with Johnson & Johnson, in ICONIC-LEAD1 and ICONIC-TOTAL2, two pivotal Phase 3 investigational studies of icotrokinra (JNJ-2113, formerly PN-235), the first-in-class targeted oral peptide that selectively blocks the IL-23 receptor, in individuals 12 years of age and older with moderate to severe plaque psoriasis (PsO)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/tm2428765d1_ex99-1.htm)) |
| 2025 | [ICOTYDE (icotrokinra) NDA/BLA submission](https://sec-api.dev/pdufa/icotrokinra) | PTGX |  | scheduled | "Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/tm258665d1_ex99-1.htm)) |
| Q1 2025 | [Protagonist Therapeutics, Inc topline data readout](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | scheduled | "Topline results for the ANTHEM trial are expected in the first quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm)) |
| February 21, 2025 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_ex99-1.htm)) |
| Mar 2025 | [Protagonist Therapeutics, Inc topline data readout](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | scheduled | "The topline data for the Phase 3 VERIFY study2 in PV, which has a 32-week primary efficacy endpoint, is expected in March of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_ex99-1.htm)) |
| March 10, 2025 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | PTGX | moderately to severely active ulcerative colitis3 | completed, positive | "Calif., March 10, 2025 - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/tm258665d1_ex99-2.htm)) |
| Q2 2025 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | PTGX |  | scheduled | "Topline results for the ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and pustular/erythrodermic psoriasis trials are expected in the second quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm)) |
| May 6, 2025 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/tm2514117d1_ex99-1.htm)) |
| August 6, 2025 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/tm2522652d1_ex99-1.htm)) |
| November 6, 2025 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "or "the Company") today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925107753/tm2530353d1_ex99-1.htm)) |
| February 25, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926019658/tm267184d1_ex99-1.htm)) |
| April 2026 | [Open-label rusfertide primary completion](https://sec-api.dev/pdufa/open-label-rusfertide) | PTGX | Polycythemia Vera | delayed | "NCT06033586 (Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-01 (ESTIMATED); Lead Sponsor Protagonist Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06033586)) |
| May 5, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | ""the Company") today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm)) |
| May 5, 2026 | [MIMRYLO™ (rusfertide) NDA/BLA acceptance](https://sec-api.dev/pdufa/rusfertide) | PTGX |  | completed | "March 2, Takeda and Protagonist announced that the U.S. FDA accepted the New Drug Application for rusfertide and granted" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm)) |
| Aug 2026 | [MIMRYLO™ (rusfertide) PDUFA date](https://sec-api.dev/pdufa/rusfertide) | PTGX |  | completed, approved | "As announced on March 2nd, the NDA for rusfertide was accepted by the FDA and granted Priority Review in Q1 2026, with a PDUFA goal date in August 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| August 5, 2026 | [MIMRYLO™ (rusfertide) NDA/BLA acceptance](https://sec-api.dev/pdufa/rusfertide) | PTGX |  | completed | "As announced on March 2nd, the NDA for rusfertide was accepted by the FDA and granted Priority Review in Q1 2026, with a PDUFA goal date in August 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| August 5, 2026 | [ICOTYDE (icotrokinra) FDA approval](https://sec-api.dev/pdufa/icotrokinra) | PTGX |  | completed, approved | "March 18, Protagonist announced that Johnson & Johnson received U.S. FDA approval of ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| August 5, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| late 2026 | [MIMRYLO™ (rusfertide) trial start](https://sec-api.dev/pdufa/rusfertide) | PTGX |  | scheduled | "PN-881 (oral IL-17 antagonist peptide): The Company expects completion of Phase 1 study by mid-2026 and initiation of a Phase 2 study by end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm)) |
| November 5, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926123351/tm2629043d1_ex99-1.htm)) |
| November 5, 2026 | [MIMRYLO™ (rusfertide) FDA approval](https://sec-api.dev/pdufa/rusfertide) | PTGX | erythrocytosis in adults with polycythemia vera | completed, approved | "Protagonist announced that its partner Takeda received U.S. Food and Drug Administration (FDA) approval of MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera (PV)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926123351/tm2629043d1_ex99-1.htm)) |

## Drugs

- [Open-label rusfertide](https://sec-api.dev/pdufa/open-label-rusfertide): Polycythemia Vera

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ptgx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PTGX catalysts: Protagonist Therapeutics, Inc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ptgx/catalysts

```bibtex
@misc{secapidev_companies_ptgx_catalysts_20261116,
  title        = {PTGX catalysts: Protagonist Therapeutics, Inc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ptgx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ptgx_catalysts_20261116","title":"PTGX catalysts: Protagonist Therapeutics, Inc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ptgx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
